Cutting-edge Research to Create Better Solutions for Prostate Cancer

April 15, 2024 Providence News Team

Providence St. Jude Crosson Cancer Institute oncologists are aggressively pursuing new answers to metastatic prostate cancer, including research into an innovative immunotherapy called AMG 509.

We are one of only a few dozen hospitals in the world and just three in California—along with City of Hope and UCSF—to offer Phase I trials of this first-in-class antibody capable of targeting prostate cancer cells.

The AMG 509 antibody binds to two different proteins, one commonly found on the surface of prostate cancer cells and one on the immune system’s T cells. “AMG 509 triggers an activation of the patient’s T cells and redirects them to cluster on and eradicate cancer cells,” explains Yung Lyou, MD, a Crosson Cancer Institute genitourinary oncologist who specializes in prostate, kidney and bladder cancers.

Men with metastatic prostate cancer who have not responded to or have refused a taxane regimen are currently being enrolled.

To learn more about any of the research trials currently underway for a wide range of cancers, please call our oncology research department at 714-446-5177.

About the Author

The Providence News Team brings you the updates to keep you informed about what's happening across the organizational ecosystem. From partnerships to new doctor announcements, we are committed to keeping you informed.
More Content by Providence News Team

Welcome to your journey for creating a healthier you

Cutting-edge Research to Create Better Solutions for Prostate Cancer

About the Author

Previous Article

Next Article

Cutting-edge Research to Create Better Solutions for Prostate Cancer

About the Author

Previous Article

Next Article

Most Recent Articles

When a stroke robbed Lauren of her balance, the team on 4K – Providence Acute Rehabilitation Center – helped her regain what she lost with a little help from sunflowers, marigolds and little bugs.

The bariatric programs at Providence Little Company of Mary’s San Pedro and Torrance locations offer effective, long-term weight-loss solutions.

Providence South Division Cancer Institute earns national recognition as a top cancer program

Hospital program the only one recognized in Greater L.A. Area

More than 2,000 years ago, Hippocrates—the father of modern medicine—suggested that all diseases begin in the gut. With mounting evidence showing a connection between gut health and everything from au

Grounding allows us to use the earth’s negative electric charge to stabilize and rebalance our body’s accumulated positive charges. Contact with the vast supply of electrons on the earth’s surface—thi

Despite the sometimes dramatic improvements that have been made in other cancers, lung cancer survival has only slightly improved over the past several decades. Fortunately, that’s beginning to change

Rob Sears had been troubled by an increasingly erratic heartbeat for years. He finally found help from Dr. Shephal Doshi and a leading-edge minimally invasive procedure.

A special request for our patients and visitors – Farsi and Spanish translation further below:

R. Bryan Bell, M.D., D.D.S., FACS, FRCS(Ed) has accepted the roles of executive medical director of Providence Cancer Institute and director of the Earle A. Chiles Research Institute.

The team at the Adult and Pediatric Cochlear Implant Program, Dr. Courtney Voelker and Dr. Rebecca Lewis, restored Father Timothy McGowan’s hearing so he could get back to the work he loves.

Kadlec offering Prevention4ME for detection of breast and other cancers.

The annual SITC meeting brings together cancer immunotherapy researchers with a goal to advance science, discover breakthroughs and educate the world on cancer immunotherapy.

In 2023, Providence Alaska contributed $265,000 to Catholic Social Services’ Medical Respite program, which provides recuperative living quarters for patients experiencing homelessness.

Learn why a proposed FSED is not right for our community.

New study evaluates a type of CAR T-cell therapy called liso-cel. Researchers will collect data from multiple groups in a study that may give patients hope for long-term remission and quality of life.

Explore promising clinical trials at Providence Cancer Institute that are investigating immunotherapy for early-stage TNBC and high-risk, HR-positive breast cancer.